Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00226980
First received: September 13, 2005
Last updated: April 10, 2009
Last verified: April 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2006
  Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)